Zimmerman Kristin, Rudolph James, Salow Marci, Skarf L Michal
Department of Pharmacy and Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, MA, USA.
Am J Hosp Palliat Care. 2011 Nov;28(7):501-10. doi: 10.1177/1049909111403732. Epub 2011 Mar 30.
Patients receiving palliative care often possess multiple risk factors and predisposing conditions for delirium. The impact of delirium on patient care in this population may also be far-reaching: affecting not only quality of remaining life but the dying process experienced by patients, caregivers, and the medical team as well. As palliative care focuses on comfort and symptom management, the approach to assessment and subsequent treatment of delirium in palliative care patients may prove difficult for providers to navigate. This article summarizes the multifactorial nature, numerous predisposing medical risk factors, neuropsychiatric adverse effects of palliative medications, pharmacokinetic changes, and challenges complicating delirium assessment and provides a systematic framework for assessment. The benefits, risks, and patient-specific considerations for treatment selection are also discussed.
接受姑息治疗的患者往往存在多种导致谵妄的风险因素和诱发条件。谵妄对这一人群患者护理的影响可能也很深远:不仅影响剩余生命的质量,还影响患者、护理人员和医疗团队所经历的死亡过程。由于姑息治疗侧重于舒适和症状管理,对于医护人员而言,评估和后续治疗姑息治疗患者谵妄的方法可能很难把握。本文总结了谵妄的多因素性质、众多诱发医学风险因素、姑息治疗药物的神经精神不良反应、药代动力学变化以及使谵妄评估复杂化的挑战,并提供了一个系统的评估框架。还讨论了治疗选择的益处、风险和针对患者的考虑因素。